Innovation in cognitive health took center stage at the Longevity World Forum 2026, held at La Nave, where Newmanbrain officially presented its groundbreaking Theia system for the early detection of Mild Cognitive Impairment (MCI).
Advancing Early Detection in Cognitive Health
Mild Cognitive Impairment represents a critical stage between normal cognitive aging and more advanced neurodegenerative conditions. Identifying it early is essential to enable timely intervention, personalized care strategies, and more effective prevention.
Theia was developed with a clear mission: to transform the way cognitive decline is detected and managed. By leveraging advanced technology and innovative methodologies, the system enables early identification of subtle cognitive changes — potentially making a significant difference in long-term brain health outcomes.
A Global Platform for Longevity Innovation
The Longevity World Forum 2026 brought together international experts, researchers, health professionals, and technology companies focused on extending healthspan and promoting healthy aging. Newmanbrain’s participation provided an opportunity to showcase how cutting-edge cognitive assessment tools can become a strategic pillar in preventive healthcare.
Throughout the event, the team engaged with numerous attendees eager to learn more about Theia’s capabilities and real-world applications. The strong interest confirmed that early cognitive screening is becoming a global priority in the longevity and healthcare ecosystems.
Special Acknowledgements
We would like to extend our sincere thanks to Irene Tortosa and Chien Lai Pan for their invaluable support in presenting the system. Their professionalism and dedication were instrumental in communicating the impact and potential of Theia to a highly specialized and international audience.
Looking Ahead
The reception at the Longevity World Forum 2026 reinforces our belief that prevention is the future of cognitive health. At Newmanbrain, we remain committed to advancing technologies like Theia that not only detect cognitive decline at its earliest stages but also help reshape the paradigm of brain health and aging.
We are confident that innovations like Theia will play a transformative role in redefining how we prevent cognitive decline worldwide.
From left to right: Chien Lai Pan (Newmanbrain Asian PR), Pablo Belmonte (Newmanbrain CEO), and Irene Tortosa (Newmanbrain Product Manager).